Published in Virology on November 01, 1990
Identification of Saccharomyces cerevisiae DNA ligase IV: involvement in DNA double-strand break repair. EMBO J (1997) 3.29
The genome of Melanoplus sanguinipes entomopoxvirus. J Virol (1999) 1.84
Mammalian DNA ligase III: molecular cloning, chromosomal localization, and expression in spermatocytes undergoing meiotic recombination. Mol Cell Biol (1995) 1.51
Identification of a poxvirus gene encoding a uracil DNA glycosylase. Proc Natl Acad Sci U S A (1993) 1.25
Vaccinia DNA ligase complements Saccharomyces cerevisiae cdc9, localizes in cytoplasmic factories and affects virulence and virus sensitivity to DNA damaging agents. EMBO J (1991) 1.19
Diversity in the acute CD8 T cell response to vaccinia virus in humans. J Immunol (2005) 1.16
Poxvirus DNA primase. Proc Natl Acad Sci U S A (2007) 1.14
Steroid hormone synthesis by a vaccinia enzyme: a new type of virus virulence factor. EMBO J (1992) 1.11
Poxvirus DNA replication. Cold Spring Harb Perspect Biol (2013) 1.02
Vaccinia virus DNA ligase recruits cellular topoisomerase II to sites of viral replication and assembly. J Virol (2008) 1.01
Cellular DNA ligase I is recruited to cytoplasmic vaccinia virus factories and masks the role of the vaccinia ligase in viral DNA replication. Cell Host Microbe (2009) 0.96
An African swine fever virus gene with homology to DNA ligases. Nucleic Acids Res (1992) 0.95
Characterization of a baculovirus-encoded ATP-dependent DNA ligase. J Virol (1998) 0.89
An etoposide-induced block in vaccinia virus telomere resolution is dependent on the virus-encoded DNA ligase. J Virol (1995) 0.79
A role for vaccinia virus protein C16 in reprogramming cellular energy metabolism. J Gen Virol (2014) 0.78
The complete DNA sequence of vaccinia virus. Virology (1990) 7.76
Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A (1982) 7.04
RNA polymerase activity in purified infectious vaccinia virus. Proc Natl Acad Sci U S A (1967) 5.49
Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions. J Biol Chem (1975) 3.66
Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci U S A (1984) 3.58
NYVAC: a highly attenuated strain of vaccinia virus. Virology (1992) 3.38
Electrophoresis of thymidine kinase activity synthesized by cells transformed by herpes simplex virus. Virology (1972) 3.05
Molecular genetics of vaccinia virus: demonstration of marker rescue. Proc Natl Acad Sci U S A (1982) 3.01
Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci U S A (1983) 2.79
Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J Virol (1981) 2.74
Vaccinia virus-encoded eIF-2 alpha homolog abrogates the antiviral effect of interferon. Virology (1991) 2.63
Reversal of the interferon-sensitive phenotype of a vaccinia virus lacking E3L by expression of the reovirus S4 gene. J Virol (1995) 2.55
Nucleotide phosphohydrolase in purified vaccinia virus. J Virol (1968) 2.35
Protein kinase and specific phosphate acceptor proteins associated with vaccinia virus cores. J Virol (1972) 2.22
Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology (1991) 2.17
Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology (1992) 2.15
Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A (1996) 2.10
Modification of the 5'-terminus of mRNA by soluble guanylyl and methyl transferases from vaccinia virus. Proc Natl Acad Sci U S A (1975) 2.10
Immunisation with canarypox virus expressing rabies glycoprotein. Lancet (1992) 2.09
Vaccinia virus host range genes. Virology (1990) 2.02
HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat Med (1995) 1.99
Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J Virol (1998) 1.98
An update on the vaccinia virus genome. Virology (1993) 1.95
Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J Virol (1989) 1.84
TAR RNA-binding protein is an inhibitor of the interferon-induced protein kinase PKR. Proc Natl Acad Sci U S A (1994) 1.80
Polyadenylate polymerase from vaccinia virions. Nat New Biol (1973) 1.76
Two nucleic acid-dependent nucleoside triphosphate phosphohydrolases from vaccinia virus. Nucleotide substrate and polynucleotide cofactor specificities. J Biol Chem (1974) 1.76
Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology (1992) 1.76
Carcinoembryonic antigens: alternative splicing accounts for the multiple mRNAs that code for novel members of the carcinoembryonic antigen family. J Cell Biol (1989) 1.72
Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine (1991) 1.66
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis (1998) 1.64
Recombinant vaccinia virus: immunization against multiple pathogens. Science (1985) 1.60
Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine (1988) 1.55
Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus. Virology (1991) 1.55
Transcriptional complexity of vaccinia virus in vivo and in vitro. J Virol (1977) 1.53
Host-range restriction of vaccinia virus E3L-specific deletion mutants. Virus Genes (1996) 1.53
Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth. J Natl Cancer Inst (1997) 1.52
Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology (1992) 1.48
High molecular weight virion-associated RNA of vaccinia. A possible precursor to 8 to 12 S mRNA. J Biol Chem (1977) 1.45
Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. Vaccine (1994) 1.43
Computerized literature searching in a teaching family practice center. Fam Pract Res J (1991) 1.42
Role of the vaccinia virus E3L and K3L gene products in rescue of VSV and EMCV from the effects of IFN-alpha. J Interferon Cytokine Res (1998) 1.38
Distinct patterns of IFN sensitivity observed in cells infected with vaccinia K3L- and E3L- mutant viruses. Virology (1995) 1.36
Vaccinia virus rifampicin-resistance locus specifies a late 63,000 Da gene product. Virology (1986) 1.35
Protective immunity against avian influenza induced by a fowlpox virus recombinant. Vaccine (1988) 1.35
Deletion of 55 open reading frames from the termini of vaccinia virus. Virology (1991) 1.34
Fowlpox virus as a vector in non-avian species. Vaccine (1988) 1.29
Recombinant vaccinia virus expression of the bovine leukaemia virus envelope gene and protection of immunized sheep against infection. Vaccine (1991) 1.28
Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J Leukoc Biol (1995) 1.27
Housing quality among North Carolina farmworker families. J Agric Saf Health (2007) 1.26
Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J Infect Dis (1995) 1.26
Some reasons for compliance and noncompliance in a health maintenance organization breast cancer screening program. J Compliance Health Care (1988) 1.25
Potential use of non-replicating vectors as recombinant vaccines. Vaccine (1992) 1.25
Vaccinia virus as an expression vector. Methods Enzymol (1987) 1.25
Vaccinia virus recombinants expressing either the measles virus fusion or hemagglutinin glycoprotein protect dogs against canine distemper virus challenge. J Virol (1991) 1.24
A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology (1992) 1.24
M protein (M1) of influenza virus: antigenic analysis and intracellular localization with monoclonal antibodies. J Virol (1989) 1.24
Molecular complexity of vaccinia DNA and the presence of reiterated sequences in the genome. Virology (1977) 1.23
Physical mapping and DNA sequence analysis of the rifampicin resistance locus in vaccinia virus. Virology (1985) 1.22
NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect Immun (1996) 1.20
Efficacy studies on a canarypox-rabies recombinant virus. Vaccine (1991) 1.20
Vaccinia: virus, vector, vaccine. Adv Virus Res (1988) 1.19
A randomized trial of a brief intervention to increase fruit and vegetable intake: a replication study among callers to the CIS. Prev Med (2001) 1.19
In vitro synthesis of a high molecular weight virion-associated RNA by vaccinia. J Biol Chem (1977) 1.17
Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques. AIDS Res Hum Retroviruses (1996) 1.16
Fusogenic segments of bovine leukemia virus and simian immunodeficiency virus are interchangeable and mediate fusion by means of oblique insertion in the lipid bilayer of their target cells. Proc Natl Acad Sci U S A (1992) 1.16
Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine (1995) 1.15
Single-stranded deoxyribonucleic acid-specific nuclease from vaccinia virus. Purification and characterization. J Biol Chem (1974) 1.14
Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. J Infect Dis (1996) 1.13
p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci U S A (1996) 1.11
Newcastle disease virus fusion protein expressed in a fowlpox virus recombinant confers protection in chickens. J Virol (1990) 1.11
Differentiation of Toxoplasma gondii from closely related coccidia by riboprint analysis and a surface antigen gene polymerase chain reaction. Am J Trop Med Hyg (1993) 1.11
Sarcocystis neurona n. sp. (Protozoa: Apicomplexa), the etiologic agent of equine protozoal myeloencephalitis. J Parasitol (1991) 1.09
Contact formation by fibroblasts adhering to heparan sulfate-binding substrata (fibronectin or platelet factor 4). Exp Cell Res (1983) 1.08
Effects of subcutaneous calcitriol administration on plasma calcium and parathyroid hormone concentrations in continuous ambulatory peritoneal dialysis uremic patients. Perit Dial Int (1993) 1.07
Equine herpesvirus type 1 unique short fragment encodes glycoproteins with homology to herpes simplex virus type 1 gD, gI and gE. J Gen Virol (1990) 1.07
Mutations in ORF D13L and other genetic loci alter the rifampicin phenotype of vaccinia virus. Virology (1993) 1.06
Regeneration of corticospinal axons in the rat. Ann Neurol (1977) 1.05
Poxvirus-based vectors as vaccine candidates. Crit Rev Immunol (1990) 1.05
Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur J Immunol (1996) 1.04
Deoxyribonucleic acid-dependent nucleotide phosphohydrolase activity in purified vaccinia virus. J Virol (1972) 1.04
Testicular cancer. Adolescent knowledge and attitudes. J Adolesc Health Care (1988) 1.04
Methyl group analysis of virion-associated high-molecular-weight RNA synthesized in vitro by purified vaccinia virus. J Virol (1977) 1.04
Evaluation of a testicular cancer curriculum for adolescents. J Pediatr (1989) 1.03